AARD (Aardvark Therapeutics) Short Interest


AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $4.79
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AARD vs TELO, OKYO, SGMO: Short Interest Comparison

For the Biotechnology subindustry, Aardvark Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aardvark Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aardvark Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Aardvark Therapeutics's Short Interest falls into.


AARD
12GF Score
Aardvark Therapeutics Inc AARD
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price